GeoVax Labs Statistics
Total Valuation
GeoVax Labs has a market cap or net worth of $13.02 million. The enterprise value is $4.33 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeoVax Labs has 9.44 million shares outstanding. The number of shares has increased by 85.56% in one year.
| Current Share Class | 9.44M |
| Shares Outstanding | 9.44M |
| Shares Change (YoY) | +85.56% |
| Shares Change (QoQ) | +152.17% |
| Owned by Insiders (%) | 0.47% |
| Owned by Institutions (%) | 3.07% |
| Float | 8.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.45 |
| Forward PS | 1.10 |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.17
| Current Ratio | 4.17 |
| Quick Ratio | 3.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,145.90 |
Financial Efficiency
Return on equity (ROE) is -276.02% and return on invested capital (ROIC) is -173.73%.
| Return on Equity (ROE) | -276.02% |
| Return on Assets (ROA) | -112.10% |
| Return on Invested Capital (ROIC) | -173.73% |
| Return on Capital Employed (ROCE) | -288.03% |
| Revenue Per Employee | $181,774 |
| Profits Per Employee | -$1.43M |
| Employee Count | 17 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.95% in the last 52 weeks. The beta is 3.07, so GeoVax Labs's price volatility has been higher than the market average.
| Beta (5Y) | 3.07 |
| 52-Week Price Change | -29.95% |
| 50-Day Moving Average | 1.73 |
| 200-Day Moving Average | 2.48 |
| Relative Strength Index (RSI) | 36.78 |
| Average Volume (20 Days) | 774,508 |
Short Selling Information
The latest short interest is 762,644, so 8.08% of the outstanding shares have been sold short.
| Short Interest | 762,644 |
| Short Previous Month | 563,016 |
| Short % of Shares Out | 8.08% |
| Short % of Float | 8.57% |
| Short Ratio (days to cover) | 1.41 |
Income Statement
In the last 12 months, GeoVax Labs had revenue of $3.09 million and -$24.32 million in losses. Loss per share was -$7.44.
| Revenue | 3.09M |
| Gross Profit | -19.25M |
| Operating Income | -24.49M |
| Pretax Income | -26.92M |
| Net Income | -24.32M |
| EBITDA | -24.40M |
| EBIT | -24.49M |
| Loss Per Share | -$7.44 |
Full Income StatementBalance Sheet
The company has $8.59 million in cash and n/a in debt, giving a net cash position of $8.59 million or $0.91 per share.
| Cash & Cash Equivalents | 8.59M |
| Total Debt | n/a |
| Net Cash | 8.59M |
| Net Cash Per Share | $0.91 |
| Equity (Book Value) | 8.50M |
| Book Value Per Share | 0.99 |
| Working Capital | 8.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.20 million and capital expenditures -$39,602, giving a free cash flow of -$27.24 million.
| Operating Cash Flow | -27.20M |
| Capital Expenditures | -39,602 |
| Free Cash Flow | -27.24M |
| FCF Per Share | -$2.89 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -792.63% |
| Pretax Margin | -787.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GeoVax Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -85.56% |
| Shareholder Yield | -85.56% |
| Earnings Yield | -188.14% |
| FCF Yield | -210.71% |
Analyst Forecast
The average price target for GeoVax Labs is $14.20, which is 928.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.20 |
| Price Target Difference | 928.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on January 31, 2024. It was a reverse split with a ratio of 0.0666667:1.
| Last Split Date | Jan 31, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0666667:1 |
Scores
GeoVax Labs has an Altman Z-Score of -18.84 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -18.84 |
| Piotroski F-Score | 1 |